US Dravet Syndrome Pricing Strategy Model

Dravet-specific pricing in the US sits on a generic valproate/clobazam backbone and three branded agents. Cannabidiol (Epidiolex, Jazz Pharmaceuticals) lists near $32,000 a year and has held a six-year branded run since 2018 with no generic entrant; ANDA litigation is settled to launch dates in the late 2030s. Fenfluramine (Fintepla, UCB) lists at a weight-based average near $96,000 a year, roughly three times cannabidiol, reflecting its stronger pivotal-trial efficacy and its REMS cardiac-monitoring burden. Stiripentol (Diacomit, Biocodex) sits well below both at roughly $10,000 to $15,000 a year, priced as an adjunct-only therapy rather than a monotherapy competitor.

Neither cannabidiol nor fenfluramine is a controlled substance today. The DEA descheduled Epidiolex in 2020 and fenfluramine in 2022, so both route through the standard Part D pharmacy benefit rather than a specialty narcotics pathway. Prior-authorization criteria are already fixed across payers: a Dravet diagnosis (clinical or SCN1A-confirmed), at least four seizures a month, and documented failure of two or more prior anti-seizure medications. Many commercial plans layer a step-edit on top, requiring a cannabidiol trial before fenfluramine is authorized, despite fenfluramine's stronger pivotal result, precisely because the three-fold price gap is the variable payers can act on. The payer mix, roughly half commercial and 45% Medicaid, means a state Medicaid strategy has to exist at launch, not after.

Every AXLRx pricing model is built from primary regulatory and manufacturer-disclosure sources, not secondary summaries. Findings are independently verified before inclusion.

US Dravet syndrome pricing sources: UCB/Zogenix and Jazz Pharmaceuticals list-price disclosures, the Fintepla FDA label and REMS requirement, DEA descheduling notices, and FDA Drugs@FDA registration records.